Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 485

1.

Erratum to "KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFκB-Mediated CCL2 Production" [Neoplasia, Volume: 21, Issue:1, (2019) 52-60].

Chen R, Keoni C, Waker CA, Lober RM, Chen YH, Gutmann DH.

Neoplasia. 2020 Mar;22(3):e1. doi: 10.1016/j.neo.2019.04.005. No abstract available.

2.

Implications of New Understandings of Gliomas in Children and Adults with NF1: Report of a Consensus Conference.

Packer RJ, Iavarone A, Jones DTW, Blakeley JO, Bouffet E, Fisher MJ, Hwang E, Hawkins C, Kilburn L, MacDonald T, Pfister SM, Rood B, Rodriguez FJ, Tabori U, Ramaswamy V, Zhu Y, Fangusaro J, Johnston SA, Gutmann DH.

Neuro Oncol. 2020 Feb 14. pii: noaa036. doi: 10.1093/neuonc/noaa036. [Epub ahead of print]

PMID:
32055852
3.

Melanoma in individuals with neurofibromatosis type 1: a retrospective study.

Zhang M, Bhat T, Gutmann DH, Johnson KJ.

Dermatol Online J. 2019 Nov 15;25(11). pii: 13030/qt5ck3f722.

4.

The Sociobiology of Brain Tumors.

Gutmann DH.

Adv Exp Med Biol. 2020;1225:115-125. doi: 10.1007/978-3-030-35727-6_8. Review.

PMID:
32030651
5.

Correction to: Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma.

Haage V, Semtner M, Vidal RO, Hernandez DP, Pong WW, Chen Z, Hambardzumyan D, Magrini V, Ly A, Walker J, Mardis E, Mertins P, Sauer S, Kettenmann H, Gutmann DH.

Acta Neuropathol Commun. 2020 Jan 8;8(1):1. doi: 10.1186/s40478-019-0875-3.

6.

Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1.

Payne JM, Haebich KM, MacKenzie R, Walsh KS, Hearps SJC, Coghill D, Barton B, Pride NA, Ullrich NJ, Tonsgard JH, Viskochil D, Schorry EK, Klesse L, Fisher MJ, Gutmann DH, Rosser T, Packer RJ, Korf B, Acosta MT, Bellgrove MA, North KN.

J Atten Disord. 2019 Dec 14:1087054719894384. doi: 10.1177/1087054719894384. [Epub ahead of print]

PMID:
31838937
7.

let-7 MicroRNAs Regulate Microglial Function and Suppress Glioma Growth through Toll-Like Receptor 7.

Buonfiglioli A, Efe IE, Guneykaya D, Ivanov A, Huang Y, Orlowski E, Krüger C, Deisz RA, Markovic D, Flüh C, Newman AG, Schneider UC, Beule D, Wolf SA, Dzaye O, Gutmann DH, Semtner M, Kettenmann H, Lehnardt S.

Cell Rep. 2019 Dec 10;29(11):3460-3471.e7. doi: 10.1016/j.celrep.2019.11.029.

8.

Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.

Payne JM, Hearps SJC, Walsh KS, Paltin I, Barton B, Ullrich NJ, Haebich KM, Coghill D, Gioia GA, Cantor A, Cutter G, Tonsgard JH, Viskochil D, Rey-Casserly C, Schorry EK, Ackerson JD, Klesse L, Fisher MJ, Gutmann DH, Rosser T, Packer RJ, Korf B, Acosta MT, North KN; NF Clinical Trials Consortium.

Ann Clin Transl Neurol. 2019 Dec;6(12):2555-2565. doi: 10.1002/acn3.50952. Epub 2019 Dec 3.

9.

Microglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology.

Gutmann DH, Kettenmann H.

Neuron. 2019 Nov 6;104(3):442-449. doi: 10.1016/j.neuron.2019.08.028. Review.

PMID:
31697921
10.

Pain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1.

Buono FD, Grau LE, Sprong ME, Morford KL, Johnson KJ, Gutmann DH.

J Pain Res. 2019 Aug 22;12:2555-2561. doi: 10.2147/JPR.S209540. eCollection 2019. Review.

11.

NF1 glioblastoma clonal profiling reveals KMT2B mutations as potential somatic oncogenic events.

Wong WH, Junck L, Druley TE, Gutmann DH.

Neurology. 2019 Dec 10;93(24):1067-1069. doi: 10.1212/WNL.0000000000008623. Epub 2019 Nov 5. No abstract available.

PMID:
31690684
12.

Microglia as Dynamic Cellular Mediators of Brain Function.

Wright-Jin EC, Gutmann DH.

Trends Mol Med. 2019 Nov;25(11):967-979. doi: 10.1016/j.molmed.2019.08.013. Epub 2019 Oct 6. Review.

PMID:
31597593
13.

Understanding a complicated Gal-1.

Hirbe AC, Gutmann DH.

Neuro Oncol. 2019 Nov 4;21(11):1341-1343. doi: 10.1093/neuonc/noz165. No abstract available.

PMID:
31538650
14.

Neurofibromatosis 2 in children presenting during the first decade of life.

Gaudioso C, Listernick R, Fisher MJ, Campen CJ, Paz A, Gutmann DH.

Neurology. 2019 Sep 3;93(10):e964-e967. doi: 10.1212/WNL.0000000000008065. Epub 2019 Jul 30.

PMID:
31363058
15.

Tenascin C regulates multiple microglial functions involving TLR4 signaling and HDAC1.

Haage V, Elmadany N, Roll L, Faissner A, Gutmann DH, Semtner M, Kettenmann H.

Brain Behav Immun. 2019 Oct;81:470-483. doi: 10.1016/j.bbi.2019.06.047. Epub 2019 Jul 2.

PMID:
31271872
16.

Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):522-523. doi: 10.1038/s41571-019-0236-y. No abstract available.

PMID:
31150022
17.
18.

Commentary: Identification of Mutation Regions on NF1 Responsible for High- and Low-Risk Development of Optic Pathway Glioma in Neurofibromatosis Type I.

Anastasaki C, Gao F, Gutmann DH.

Front Genet. 2019 Mar 1;10:115. doi: 10.3389/fgene.2019.00115. eCollection 2019. No abstract available.

19.

Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma.

Haage V, Semtner M, Vidal RO, Hernandez DP, Pong WW, Chen Z, Hambardzumyan D, Magrini V, Ly A, Walker J, Mardis E, Mertins P, Sauer S, Kettenmann H, Gutmann DH.

Acta Neuropathol Commun. 2019 Feb 14;7(1):20. doi: 10.1186/s40478-019-0665-y. Erratum in: Acta Neuropathol Commun. 2020 Jan 8;8(1):1.

20.

Challenges to curing primary brain tumours.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):509-520. doi: 10.1038/s41571-019-0177-5. Review.

21.

Adaptive functioning in children with neurofibromatosis type 1: relationship to cognition, behavior, and magnetic resonance imaging.

Eby NS, Griffith JL, Gutmann DH, Morris SM.

Dev Med Child Neurol. 2019 Aug;61(8):972-978. doi: 10.1111/dmcn.14144. Epub 2019 Jan 18.

PMID:
30659594
22.

Clearing the Fog surrounding Chemobrain.

Gutmann DH.

Cell. 2019 Jan 10;176(1-2):2-4. doi: 10.1016/j.cell.2018.12.027.

23.

Neurofibromatosis type 1 (Nf1)-mutant mice exhibit increased sleep fragmentation.

Anastasaki C, Rensing N, Johnson KJ, Wong M, Gutmann DH.

J Sleep Res. 2019 Aug;28(4):e12816. doi: 10.1111/jsr.12816. Epub 2019 Jan 4.

PMID:
30609083
24.

KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFκB-Mediated CCL2 Production.

Chen R, Keoni C, Waker CA, Lober RM, Chen YH, Gutmann DH.

Neoplasia. 2019 Jan;21(1):52-60. doi: 10.1016/j.neo.2018.11.007. Epub 2018 Nov 30. Erratum in: Neoplasia. 2020 Mar;22(3):e1.

25.

Variability of Betweenness Centrality and Its Effect on Identifying Essential Genes.

Durón C, Pan Y, Gutmann DH, Hardin J, Radunskaya A.

Bull Math Biol. 2019 Sep;81(9):3655-3673. doi: 10.1007/s11538-018-0526-z. Epub 2018 Oct 22.

PMID:
30350013
26.

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1.

Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, Stemmer-Rachamimov AO, Fahrenkrug SC, Gutmann DH, Giovannini M, Moertel CL, Largaespada DA, Watson AL.

Commun Biol. 2018 Oct 2;1:158. doi: 10.1038/s42003-018-0163-y. eCollection 2018.

27.

Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1.

Griffith JL, Morris SM, Mahdi J, Goyal MS, Hershey T, Gutmann DH.

Neurol Clin Pract. 2018 Aug;8(4):283-291. doi: 10.1212/CPJ.0000000000000494.

28.

Independent NF1 mutations underlie café-au-lait macule development in a woman with segmental NF1.

Freret ME, Anastasaki C, Gutmann DH.

Neurol Genet. 2018 Jul 23;4(4):e261. doi: 10.1212/NXG.0000000000000261. eCollection 2018 Aug. No abstract available.

29.

Height Growth Impairment in Children With Neurofibromatosis Type 1 Is Characterized by Decreased Pubertal Growth Velocity in Both Sexes.

Zessis NR, Gao F, Vadlamudi G, Gutmann DH, Hollander AS.

J Child Neurol. 2018 Oct;33(12):762-766. doi: 10.1177/0883073818786807. Epub 2018 Jul 16.

PMID:
30009646
30.

Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.

Pan Y, Duron C, Bush EC, Ma Y, Sims PA, Gutmann DH, Radunskaya A, Hardin J.

PLoS One. 2018 May 22;13(5):e0190001. doi: 10.1371/journal.pone.0190001. eCollection 2018.

31.

Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.

Freret ME, Gutmann DH.

J Neurosci Res. 2019 Jan;97(1):45-56. doi: 10.1002/jnr.24250. Epub 2018 Apr 28. Review.

32.

Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth.

Pan Y, Xiong M, Chen R, Ma Y, Corman C, Maricos M, Kindler U, Semtner M, Chen YH, Dahiya S, Gutmann DH.

Genes Dev. 2018 Apr 1;32(7-8):491-496. doi: 10.1101/gad.310797.117. Epub 2018 Apr 9.

33.

β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors.

Hirbe AC, Zhang X, Dahiya S, Godec A, Chrisinger J, Tao Y, Luo J, Gutmann DH.

Neuro Oncol. 2018 May 18;20(6):858-860. doi: 10.1093/neuonc/noy038. No abstract available.

34.

A Conserved Circadian Function for the Neurofibromatosis 1 Gene.

Bai L, Lee Y, Hsu CT, Williams JA, Cavanaugh D, Zheng X, Stein C, Haynes P, Wang H, Gutmann DH, Sehgal A.

Cell Rep. 2018 Mar 27;22(13):3416-3426. doi: 10.1016/j.celrep.2018.03.014.

35.

Neurofibromatosis type 1.

Cimino PJ, Gutmann DH.

Handb Clin Neurol. 2018;148:799-811. doi: 10.1016/B978-0-444-64076-5.00051-X. Review.

PMID:
29478615
36.

A genotype-phenotype correlation for quantitative autistic trait burden in neurofibromatosis 1.

Morris SM, Gutmann DH.

Neurology. 2018 Feb 20;90(8):377-379. doi: 10.1212/WNL.0000000000005000. Epub 2018 Jan 24. No abstract available.

PMID:
29367450
37.

Optic Pathway Gliomas in Neurofibromatosis Type 1.

Campen CJ, Gutmann DH.

J Child Neurol. 2018 Jan;33(1):73-81. doi: 10.1177/0883073817739509. Review.

38.

Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.

Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou C, Loh SN, Gutmann DH, Bourboulia D, Bratslavsky G, Wong M, Mollapour M.

EMBO J. 2017 Dec 15;36(24):3650-3665. doi: 10.15252/embj.201796700. Epub 2017 Nov 10.

39.

Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future.

Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E, Miettinen MM, Randall RL, Ratner N, Jumbé NL, Bakker A, Viskochil D, Widemann BC, Stewart DR.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx124. Review.

40.

Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights.

Khatua S, Gutmann DH, Packer RJ.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26838. Epub 2017 Oct 19. Review.

PMID:
29049847
41.

Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner.

Zou J, Zhang B, Gutmann DH, Wong M.

Epilepsia. 2017 Dec;58(12):2053-2063. doi: 10.1111/epi.13923. Epub 2017 Oct 12.

42.

Children with 5'-end NF1 gene mutations are more likely to have glioma.

Anastasaki C, Morris SM, Gao F, Gutmann DH.

Neurol Genet. 2017 Sep 22;3(5):e192. doi: 10.1212/NXG.0000000000000192. eCollection 2017 Oct.

43.

Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature.

Pan Y, Bush EC, Toonen JA, Ma Y, Solga AC, Sims PA, Gutmann DH.

Oncotarget. 2017 Apr 18;8(32):52474-52487. doi: 10.18632/oncotarget.17193. eCollection 2017 Aug 8.

44.

Neurodevelopmental disorders in children with neurofibromatosis type 1.

Vogel AC, Gutmann DH, Morris SM.

Dev Med Child Neurol. 2017 Nov;59(11):1112-1116. doi: 10.1111/dmcn.13526. Epub 2017 Aug 27. Review.

45.

Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.

Maloney SE, Chandler KC, Anastasaki C, Rieger MA, Gutmann DH, Dougherty JD.

Autism Res. 2018 Jan;11(1):44-58. doi: 10.1002/aur.1853. Epub 2017 Aug 26.

46.

The Tropism of Pleiotrophin: Orchestrating Glioma Brain Invasion.

Gutmann DH.

Cell. 2017 Aug 24;170(5):821-822. doi: 10.1016/j.cell.2017.08.011.

47.

Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA.

J Neuroophthalmol. 2017 Sep;37 Suppl 1:S23-S32. doi: 10.1097/WNO.0000000000000550. Review.

PMID:
28806346
48.

Updated nomenclature for human and mouse neurofibromatosis type 1 genes.

Anastasaki C, Le LQ, Kesterson RA, Gutmann DH.

Neurol Genet. 2017 Jul 26;3(4):e169. doi: 10.1212/NXG.0000000000000169. eCollection 2017 Aug. No abstract available.

49.

The power of the few.

Chen R, Pan Y, Gutmann DH.

Genes Dev. 2017 Jun 15;31(12):1177-1179. doi: 10.1101/gad.303453.117. Review.

50.

CNS Tumors in Neurofibromatosis.

Campian J, Gutmann DH.

J Clin Oncol. 2017 Jul 20;35(21):2378-2385. doi: 10.1200/JCO.2016.71.7199. Epub 2017 Jun 22. Review.

Supplemental Content

Loading ...
Support Center